Tuesday, 30 June 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 30 June 2026
News

TGA win lands just in time

 Posted 30 June 2026 AM

With just days to spare before the PBAC meets next month, Ipsen has secured TGA approval for Bylvay, the first medicine specifically approved in Australia for treating cholestatic pruritus in patients with Alagille Syndrome (ALGS) aged six months or older.

Ipsen failed to win a recommendation for Bylvay in ALGS in March but after accepting the early re-entry pathway, the drug will be considered again by the PBAC when it meets over three days from 8 July. Bylvay was listed on the PBS in January for a different indication: progressive familial intrahepatic cholestasis.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (22)

Access & Reimbursement (2)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.